Skip to main content

Tadalafil (Erectile Dysfunction, Benign Prostatic Hyperplasia) (Monograph)

Brand names: Cialis, Entadfi
Drug class: Calcium-Channel Blocking Agents

Medically reviewed by Drugs.com on Apr 10, 2024. Written by ASHP.

Introduction

Vasodilating agent; a selective phosphodiesterase (PDE) type 5 inhibitor.1

Uses for Tadalafil (Erectile Dysfunction, Benign Prostatic Hyperplasia)

Erectile Dysfunction

Used for the treatment of erectile dysfunction (ED, impotence).1 3 4 6 7 8 9 59 60 61

May be used as needed (on demand) or on a daily basis (without regard to timing of sexual activity).1 59 60 61

Experts recommend a selective PDE type 5 inhibitor as first-line therapy for ED unless contraindicated.189 601 602 Evidence currently insufficient to support superiority of one selective PDE type 5 inhibitor over another.189 601 602

Benign Prostatic Hyperplasia

Used as monotherapy or in fixed combination with finasteride (finasteride/tadalafil) for symptomatic management (e.g., to improve lower urinary tract symptoms) of benign prostatic hyperplasia (BPH, benign prostatic hypertrophy).1 2 81 82 83 84 89

Not recommended for use in combination with an α-adrenergic blocking agent (e.g., doxazosin, terazosin); inadequate data and potential for additive hypotensive effects.1 2 604

Concomitant ED and BPH

Treatment of both ED and symptomatic BPH in men with such coexisting conditions.1 82 89

Tadalafil (Erectile Dysfunction, Benign Prostatic Hyperplasia) Dosage and Administration

General

Pretreatment Screening

Patient Monitoring

Dispensing and Administration Precautions

Administration

Oral Administration

Tadalafil Monotherapy

Administer orally without regard to meals.1

May be administered as needed (just prior to [e.g., ≥0.5 hours before] anticipated sexual activity) or on a daily basis (at approximately the same time every day) for treatment of ED; take entire dose and do not split tablets.1 Because of prolonged duration of action (up to 36 hours),1 4 7 9 timing of administration relative to anticipated sexual activity is less important than with relatively short-acting drugs for ED.3 9

Administer as a once-daily dose at approximately the same time every day in patients with BPH with or without coexisting ED.1 When tadalafil is initiated with finasteride, administer as a once-daily dose at approximately the same time every day.1 The incremental benefit of tadalafil beyond 26 weeks in such patients is unknown.2

If a dose is missed, take the dose as soon as it is remembered but do not take more than one dose per day.1

Finasteride/Tadalafil Fixed-combination Therapy

Administer orally on an empty stomach.2

Administer fixed-combination capsule as a once-daily dose at approximately the same time every day for treatment of BPH.2 The incremental benefit of tadalafil beyond 26 weeks is unknown.2

If a dose is missed, take the dose as soon as it is remembered but do not take more than one dose per day.2

Dosage

Adults

ED
Oral

As-needed therapy: Usual initial dose is 10 mg just prior (e.g., at least 0.5 hours before) to anticipated sexual activity.1 Depending on effectiveness and tolerance, may increase dose to 20 mg or decrease to 5 mg.1 Maximum recommended dosing frequency is once daily for most patients.1 Concomitant use with HIV protease inhibitors or with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) requires dosage adjustment (see Drug Interactions).1 200

Once-daily therapy: Initially, 2.5 mg once daily.1 Depending on effectiveness and tolerance, may increase dosage to 5 mg once daily.1 Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) requires dosage adjustment (see Drug Interactions).1 200

BPH
Oral

5 mg once daily.1

Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) requires dosage adjustment (see Drug Interactions).1 200

Finasteride/tadalafil fixed-combination therapy: 5 mg of finasteride and 5 mg of tadalafil once daily as the fixed combination for up to 26 weeks.2

Concomitant ED and BPH
Oral

5 mg once daily.1

Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) requires dosage adjustment (see Drug Interactions).1 200

Special Populations

Hepatic Impairment

As-needed use for ED: In patients with mild or moderate hepatic impairment (Child-Pugh class A or B), maximum dosage is 10 mg once per day.1

Once-daily use for BPH and/or ED: Use with caution in patients with mild or moderate hepatic impairment.1

Finasteride/tadalafil fixed-combination therapy: Caution advised for mild or moderate hepatic impairment (Child-Pugh class A or B); not recommended for severe hepatic impairment (Child-Pugh class C).2

Renal Impairment

As-needed use for ED: In patients with Clcr 30–50 mL/minute, reduce initial dose to 5 mg, administered no more frequently than once daily; maximum dose 10 mg, administered no more frequently than once every 48 hours.1 For patients with Clcr<30 mL/minute or those undergoing hemodialysis, maximum dose 5 mg, administered no more frequently than once every 72 hours.1

Once-daily use for ED: Dosage adjustments not necessary in patients with Clcr ≥30 mL/minute.1 Use not recommended in patients with Clcr <30 mL/minute or those on hemodialysis.1

Once-daily use for BPH with or without ED: For Clcr 30–50 mL/minute, initial dosage of 2.5 mg once daily recommended; may increase to 5 mg once daily based on patient response and tolerance.1 Use not recommended in patients with Clcr <30 mL/minute or those on hemodialysis.1

Finasteride/tadalafil fixed combination: Not recommended in patients with Clcr <50 mL/minute or on hemodialysis.2

Geriatric Patients

No dosage adjustments necessary based solely on age.1 2

Cautions for Tadalafil (Erectile Dysfunction, Benign Prostatic Hyperplasia)

Contraindications

Warnings/Precautions

Patient Assessment

Thorough medical history and physical examination is recommended to determine potential underlying causes and identify appropriate treatment options for ED and/or BPH.1 14 15 18 19 20 21 161

Prior to initiating therapy in patients with BPH, consider possibility of other urologic conditions, including prostate cancer, that may cause similar symptoms.1

Carefully monitor patients with large residual urinary volume and/or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for finasteride/tadalafil.2

Cardiovascular Effects

Safety and efficacy for treatment of ED not established and use not recommended in patients with a recent MI (within 90 days) or stroke (within 6 months); uncontrolled arrhythmias, hypotension (<90/50 mm Hg systolic/diastolic BP) or uncontrolled hypertension; heart failure (>NYHA class II) in the previous 6 months; or those with unstable angina or angina occurring during sexual intercourse.1

Possible hypotension, particularly in patients with left-ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and in patients with severely impaired autonomic control of blood pressure.1 Additive BP-lowering effects may occur when used concomitantly with other vasodilating agents (e.g., α-adrenergic blocking agents or other antihypertensive drugs, alcohol, riociguat).1 247

Potentiation of hypotensive effect with organic nitrates, which may result in life-threatening hypotension and/or hemodynamic compromise; concomitant use contraindicated.1

Consider whether patients with underlying cardiovascular disease could be adversely affected by tadalafil’s vasodilatory activity, especially in combination with sexual activity.1

Concomitant Administration with α-Adrenergic Blocking Agents

Use with caution in patients receiving α-adrenergic blocking agents; possible potentiation of hypotensive effects due to additive vasodilatory action.1 In some cases, dosage adjustments are necessary, while in other cases, concomitant administration not recommended.1

Safety of concomitant therapy also may be affected by intravascular volume depletion and use of additional antihypertensive agents.1

Ocular Effects

Nonarteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, reported rarely during postmarketing experience in temporal association with use of all PDE type 5 inhibitors.1 37 38 39 43 44 Potential increased risk of NAION in the second eye in patients who have already experienced NAION in one eye.1

Use not recommended in patients with hereditary degenerative retinal disorders, including retinitis pigmentosa.1

Otic Effects

Sudden decrease or loss of hearing reported in temporal association with all PDE type 5 inhibitors.1

It is unclear whether such effects are directly related to PDE type 5 inhibitors or to other factors.1

Priapism

Possible prolonged erections (>4 hours) and priapism (painful erection >6 hours).1

May result in penile tissue damage and permanent loss of potency if priapism is not treated immediately.1 Use with caution in patients with conditions that may predispose to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia) and in those with anatomic deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie’s disease).1

Concomitant Administration with Potent CYP3A4 Inhibitors or Inducers

Consider potential for increased or decreased tadalafil concentrations when used concomitantly with potent inhibitors or inducers of CYP3A4; in some cases, dosage adjustments may be necessary, while in other cases, concomitant administration not recommended.1 2 200

Concomitant Use with Other PDE Type 5 Inhibitors or ED Therapies

Safety and efficacy not established for use in combination with other PDE type 5 inhibitors or other treatments for ED; do not use concomitantly with other PDE type 5 inhibitors.1

Hematologic Effects

Tadalafil inhibits PDE type 5, which is found in platelets.1 Although increase in bleeding time not observed in healthy individuals, manufacturer recommends caution in patients with bleeding disorders or substantial, active peptic ulcers; carefully weigh risks versus benefits of therapy.1

Counseling Patients on Sexually Transmitted Diseases

Patients should be advised that use of tadalafil provides no protection against sexually transmitted diseases, including HIV infection, and they should be counseled regarding protective measures to guard against such transmission.1

Potential for Drug Interactions with Once-daily Use

Once-daily tadalafil monotherapy or finasteride/tadalafil fixed-combination therapy provides continuous tadalafil plasma drug levels.1 2

Consider potential for interactions with medications (e.g., nitrates, α-adrenergic blocking agents, anti-hypertensives and potent inhibitors of CYP3A4) and substantial consumption of alcohol.1 2

Concomitant Use with Alcohol

Alcohol and PDE type 5 inhibitors are both vasodilators; combined use may have additive BP-lowering effects.1 2

Orthostatic hypotension, manifested by increased heart rate, decreased standing BP, dizziness, and headache may occur with consumption of substantial amounts of alcohol (e.g., ≥ 5 glasses of wine or 5 shots of whiskey).1 2

Use of Fixed Combinations

When tadalafil is used in fixed combination with finasteride, consider the usual cautions, precautions, and contraindications associated with finasteride in addition to those associated with tadalafil.2

Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection (Finasteride/Tadalafil)

Finasteride causes decreased serum PSA concentrations (approximately 50%) within 6 months; PSA decreases can occur even in those with prostate cancer.2 604

Establish a new PSA baseline at least 6 months after starting finasteride/tadalafil; monitor PSA periodically thereafter.2

Carefully evaluate any confirmed increase in serum PSA concentration during therapy, even if PSA is within normal range for men not receiving finasteride.2

Noncompliance may affect PSA concentrations; consider when evaluating test results.2

Increased Risk of High-Grade Prostate Cancer (Finasteride/Tadalafil)

Finasteride may increase risk of high-grade prostate cancer.2

Hypersensitivity Reactions (Finasteride/Tadalafil)

Stevens-Johnson syndrome, exfoliative dermatitis, pruritis, urticaria, and angioedema reported.2 Contraindicated in patients with a history of hypersensitivity reactions to finasteride or tadalafi.2

Risk to Male Fetus from Topical Exposure to Pregnant Females (Finasteride/Tadalafil)

May cause fetal harm; teratogenicity demonstrated in animals.2

Abnormal development of external genitalia in a male fetus may occur.2

Because of potential for absorption through skin and subsequent potential risk to a male fetus, pregnant females should not handle crushed or open finasteride/tadalafil capsules.2 If such contact occurs, wash affected area immediately with soap and water.2

Specific Populations

Pregnancy

Tadalafil (Cialis) not indicated for use in women.1

Finasteride/tadalafil (Entadfi™): Contraindicated in pregnancy; not indicated for use in females.2 Finasteride may cause fetal harm; teratogenicity demonstrated in animals.2

Lactation

Excreted into milk in rats.1 Not known if tadalafil is excreted into milk in humans.1

Tadalafil and finasteride/tadalafil not indicated for use in women.1 2

Females and Males of Reproductive Potential

Decreased sperm concentrations observed in human studies; however, clinical significance unknown.1 2

No studies evaluating the effect of tadalafil on fertility in men or women.1 2

Pediatric Use

Safety and efficacy not established in patients <18 years of age.1

Geriatric Use

Safety and efficacy in those >65 years of age is similar to that in younger patients.1 8 Possibility exists of greater sensitivity to the drug in some geriatric individuals.1

Hepatic Impairment

Insufficient experience in patients with severe hepatic impairment (Child-Pugh C); use not recommended.1 88

Data limited in patients with mild or moderate hepatic impairment (Child-Pugh class A or B) receiving once-daily tadalafil for ED, BPH, or for both conditions; caution advised in such patients.1 Dosage adjustments recommended in patients with mild or moderate hepatic impairment receiving as-needed therapy for ED.1

Finasteride/tadalafil: finasteride is extensively metabolized in liver; effect of hepatic impairment on finasteride not studied.2

Renal Impairment

Use of once-daily tadalafil not recommended in any patient with severe renal impairment.1

Dosage adjustments recommended in patients with moderate to severe renal impairment receiving once-daily or as-needed tadalafil for ED.1

Finasteride/tadalafil: Use not recommended in patients with Clcr<50 mL/minute or on hemodialysis.2

Common Adverse Effects

Tadalafil (Cialis and generic equivalents): Most common adverse effects (≥2%) include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, limb pain.1

Finasteride/tadalafil: Most common adverse effects (≥1%) include impotence, decreased libido, decreased volume of ejaculate, breast enlargement, breast tenderness, rash.2

Drug Interactions

Metabolized principally by CYP3A4.1 Does not appear to induce or inhibit the clearance of other drugs metabolized by P-glycoprotein (P-gp) or CYP isoforms 1A2, 3A4, 2C9, 2C19, 2D6, or 2E1.1

Drugs Affecting or Affected by Hepatic Microsomal Enzymes

Potent inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased tadalafil exposure).1 200 In some cases, manufacturer and experts recommend tadalafil dosage adjustments, maximum doses, and/or monitoring for safety or effectiveness during concomitant therapy, while in other cases (i.e., finasteride/tadalafil fixed-combination therapy), concomitant use not recommended.1 2 200

Potent inducers of CYP3A: Potential pharmacokinetic interaction (decreased tadalafil exposure) and possible decreased efficacy of tadalafil; however, magnitude of such decreased effectiveness is unknown.1 200 Some experts recommend tadalafil dose titration based on clinical effect when these drugs are taken concomitantly.200 Coadministration with finasteride/tadalafil not recommended.2

Specific Drugs and Foods

Drug or Food

Interaction

Comments

α-Adrenergic blocking agents (e.g., doxazosin, terazosin)

Possible symptomatic hypotension 1 604

Patients with ED: In those who are stable on an α-adrenergic blocker, initiate tadalafil at lowest recommended dosage; in those currently receiving tadalafil, initiate α-adrenergic blocker at the lowest recommended dosage1

Patients with BPH: Concomitant use not recommended; in patients already receiving an α-adrenergic blocking agent, discontinue such therapy ≥1 day prior to initiating tadalafil1

Alcohol

Possible additive hypotensive effects with heavy alcohol ingestion (e.g., ≥180 mL of 80 proof vodka) 1

Do not use alcohol excessively (e.g., ≥5 glasses of wine or shots of whiskey)

Amlodipine

Possible additive hypotensive effects1

Angiotensin II receptor antagonists

Potential additive hypotensive effects1

Antacids (aluminum and magnesium hydroxide)

Possible delayed absorption of tadalafil 1

Anticonvulsants (carbamazepine, phenytoin, phenobarbital)

Possible decreased exposure of tadalafil and decreased effectiveness of once-daily tadalafil1

Tadalafil: No dosage adjustments recommended1

Finasteride/tadalafil: Use not recommended2

Antifungal agents, azole (i.e., itraconazole, ketoconazole)

Possible increased AUC and peak plasma concentrations of tadalafil1

As-needed tadalafil for ED: Maximum dosage 10 mg once every 72 hours1

Once-daily tadalafil for BPH and/or ED: Do not exceed 2.5 mg once daily1

Antiretroviral agents, HIV protease inhibitors (e.g., atazanavir, darunavir, fosamprenavir, lopinavir/ritonavir, ritonavir, saquinavir, tipranavir)

Increased tadalafil AUC1 200

Ritonavir: Increased systemic exposure of tadalafil by more than twofold after first concurrent dose; however, no change in tadalafil exposure at steady-state ritonavir concentrations1 87

As-needed tadalafil for ED: Initial dose of 5 mg recommended; do not exceed 10 mg every 72 hours1 200

Once-daily tadalafil: Maximum dose of 2.5 mg recommended1

Finasteride/tadalafil: Use with caution2

Antiretroviral agents, HIV nonnucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine, etravirine)

Decreased tadalafil exposure200

Tadalafil dose titration based on clinical effect may be required200

Aspirin

No increase in bleeding time reported1

Bendroflumethiazide

Possible additive hypotensive effects1

Digoxin

Clinically important pharmacokinetic interaction not observed1

Enalapril

Possible additive hypotensive effects1

Erythromycin

Potential increased AUC of tadalafil 1

Grapefruit juice

Potential increased AUC of tadalafil 1

Lovastatin

Systemic exposure of lovastatin not substantially affected1

Metoprolol

Possible additive hypotensive effects1

Midazolam

Systemic exposure of midazolam not substantially affected1

Nitrates and nitrites (e.g., nitroglycerin, isosorbide dinitrate, amyl nitrite)

Potentiation of hypotensive effect1

Concomitant use is contraindicated1 4 5 8 10

If nitrate administration necessary for a life-threatening condition, allow ≥48 hours to elapse between tadalafil administration and nitrate use;1 10 administer under close supervision with caution and appropriate hemodynamic monitoring1

Nizatidine

Clinically important effects on tadalafil pharmacokinetics not observed1

Rifampin

Possible decreased systemic exposure and peak plasma concentrations of tadalafil1

Tadalafil: No dosage adjustments recommended1

Finasteride/tadalafil: Avoid use2

Riociguat

Possible additive hypotensive effects247

Concomitant use contraindicated247

Theophylline

Pharmacokinetic interaction unlikely1

Slight increase in heart rate (3 bpm) with concomitant therapy1

Warfarin

Clinically important effects on tadalafil pharmacokinetics not observed1

Tadalafil (Erectile Dysfunction, Benign Prostatic Hyperplasia) Pharmacokinetics

Absorption

Bioavailability

Absolute bioavailability unknown.1 Peak plasma concentrations usually attained within 0.5–6 hours.1

Onset

Following a single oral dose, effects were obtained within 20 minutes.1 602

Duration

Improved erection up to 24-36 hours.602

Food

Food does not appear to affect absorption.1

Distribution

Extent

Distributed into tissues.1

Plasma Protein Binding

Approximately 94%.1

Elimination

Metabolism

Metabolized in the liver, principally by CYP3A4, to inactive metabolites.1 602

Elimination Route

Excreted principally as metabolites in the feces (61%) and urine (36%).1 Not appreciably removed by hemodialysis.1 88

Half-life

17.5 hours.1 602

Special Populations

In patients with diabetes mellitus, AUC and peak plasma concentrations are decreased compared with healthy individuals.1

Clearance reduced in patients ≥65 years of age compared with younger adults, in patients with renal impairment (Clcr30-80 mL/minute) including end-stage renal disease on hemodialysis, in patients with mild or moderate hepatic impairment (Child-Pugh class A or class B), and in patients with diabetes mellitus.1

Stability

Storage

Oral

Tablets (Tadalafil)

25°C (excursions permitted to 15–30°C).1

Capsules (Finasteride/Tadalafil)

20–25°C (excursions permitted to 15–30°C).2

Actions

Advice to Patients

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Tadalafil

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

2.5 mg

Cialis

Lilly

5 mg

Cialis

Lilly

10 mg

Cialis

Lilly

20 mg

Cialis

Lilly

Tadalafil Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

5 mg of finasteride with 5 mg of tadalafil

Entadfi

Veru

AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Eli Lilly and Company. Cialis (tadalafil) tablets prescribing information. Indianapolis, IN; 2023 Apr.

2. Veru, Inc. Entadfi (finasteride and tadalafil) capsules prescribing information. Miami, Fl; 2021 Dec.

3. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003; 92:9M-18M.. http://www.ncbi.nlm.nih.gov/pubmed/14609619?dopt=AbstractPlus

4. Anon. Tadalafil (cialis) for erectile dysfunction. Med Lett Drugs Ther. 2003; 45:101-2..

5. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol. 2003; 92:37M-46M.. http://www.ncbi.nlm.nih.gov/pubmed/14609622?dopt=AbstractPlus

6. Saenz de Tejada I, Knight JR, Anglin G et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002; 25:2159-64. http://www.ncbi.nlm.nih.gov/pubmed/12453954?dopt=AbstractPlus

7. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002; 165:1332-6.

8. Curran M, Keating G. Tadalafil. Drugs. 2003;63:2203-12.

9. Porst H, Padma-Nathan H, Giuliano F et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003; 62:121-5.. http://www.ncbi.nlm.nih.gov/pubmed/12837435?dopt=AbstractPlus

10. Kloner RA, Hutter AM, Emmick JT et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003; 42:1855-60.. http://www.ncbi.nlm.nih.gov/pubmed/14642699?dopt=AbstractPlus

12. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003; 92:47M-57M..

14. National Institutes of Health Office of Medical Applications of Research. Consensus Conference: impotence. JAMA. 1993; 270:83-90. http://www.ncbi.nlm.nih.gov/pubmed/8510302?dopt=AbstractPlus

15. Wagner G, de Tejada IS. Update on male erectile dysfunction. BMJ. 1998; 316:678-82.. http://www.ncbi.nlm.nih.gov/pubmed/9522795?dopt=AbstractPlus

18. The Process of Care Consensus Panel. Position paper: the process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res. 1999; 11:59-70..

19. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol. 1999; 10:1381-8.. http://www.ncbi.nlm.nih.gov/pubmed/10361878?dopt=AbstractPlus

20. Meinhardt W, Kropman RF, Vermeij P. Comparative tolerability and efficacy of treatments for impotence. Drug Saf. 1999; 20:133-146.. http://www.ncbi.nlm.nih.gov/pubmed/10082071?dopt=AbstractPlus

21. Petak SM, Baskin HJ, Bergman DA. AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients. From American Association of Clinical Endocrinologists web site. http://www.aace.com/pub/pdf/guidelines/hypogonadism.pdf

30. Padma-Nathan H. A new era in the treatment of erectile dysfunction. Am J Cardiol. 1999; 84:18N-23N.. http://www.ncbi.nlm.nih.gov/pubmed/10404845?dopt=AbstractPlus

37. Egan RA, Fraunfelder FW. Viagra and anterior ischemic optic neuropathy. Arch Ophthalmol. 2005; 123:709-10.. http://www.ncbi.nlm.nih.gov/pubmed/15883302?dopt=AbstractPlus

38. Anon. Viagra and loss of vision. Med Lett Drugs Ther. 2005; 47:49.. http://www.ncbi.nlm.nih.gov/pubmed/15961969?dopt=AbstractPlus

39. Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol. 2000; 118:291-2.. http://www.ncbi.nlm.nih.gov/pubmed/10676804?dopt=AbstractPlus

43. Bollinger KL, Lee MS. Recurrent visual field defect and ischemic optic neuropathy assciated with tadalafil rechallenge. Arch Ophthalmol. 2005; 123:400-1.. http://www.ncbi.nlm.nih.gov/pubmed/15767488?dopt=AbstractPlus

44. Escaravage GK, Wright JD, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol. 2005; 123:399-400.. http://www.ncbi.nlm.nih.gov/pubmed/15767487?dopt=AbstractPlus

59. Hatzichristou D, Gambla M, Rubio-Aurioles E et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008; 25:138-46.. http://www.ncbi.nlm.nih.gov/pubmed/18290855?dopt=AbstractPlus

60. Rajfer J, Aliotta PJ, Steidle CP et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007 Jan-Feb; 19:95-103..

61. Porst H, Giuliano F, Glina S et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006; 50:351-9.. http://www.ncbi.nlm.nih.gov/pubmed/16766116?dopt=AbstractPlus

81. Porst H, Kim ED, Casabé AR et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60:1105-13.. http://www.ncbi.nlm.nih.gov/pubmed/21871706?dopt=AbstractPlus

82. Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012; 9:271-81.. http://www.ncbi.nlm.nih.gov/pubmed/21981682?dopt=AbstractPlus

83. Donatucci CF, Brock GB, Goldfischer ER et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011; 107:1110-6.. http://www.ncbi.nlm.nih.gov/pubmed/21244606?dopt=AbstractPlus

84. Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011; 72:197-204.. http://www.ncbi.nlm.nih.gov/pubmed/21745238?dopt=AbstractPlus

86. Spence R, Mandagere A, Harrison B et al. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci. 2009; 98:4962-74.. http://www.ncbi.nlm.nih.gov/pubmed/19455620?dopt=AbstractPlus

87. Garraffo R, Lavrut T, Ferrando S et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011; 51:1071-8.. http://www.ncbi.nlm.nih.gov/pubmed/21209236?dopt=AbstractPlus

88. Forgue ST, Phillips DL, Bedding AW et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol. 2007; 63:24-35.. http://www.ncbi.nlm.nih.gov/pubmed/16869816?dopt=AbstractPlus

89. Gonzalez RR, Kaplan SA. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol. 2006; 2:609-17.. http://www.ncbi.nlm.nih.gov/pubmed/16859408?dopt=AbstractPlus

100. Casabé A, Roehrborn CG, Da Pozzo LF et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol.2014 Mar;191(3):727-33. Doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2. PMID: 24096118.

161. Guay AT, Spark RF, Bansal S et al; American Association of Clinical Endocrinologists Male Sexual Dysfunction Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract.2003 Jan-Feb;9(1):77-95. doi: 10.4158/EP.9.1.77. PMID: 12917096.

189. Burnett AL, Nehra A, Breau RH et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018 Sep;200(3):633-641. doi: 10.1016/j.juro.2018.05.004. Epub 2018 May 7. Erratum in: J Urol. 2022 Mar;207(3):743. PMID: 29746858.

200. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services (Jan 20, 2022). Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed 25 Jan 2023. .

247. Bayer Healthcare Pharmaceuticals Inc. Adempas (riociguat) tablets prescribing information. Whippany, NJ; 2021 Sep.

601. Karakus S, Burnett AL. The medical and surgical treatment of erectile dysfunction: a review and update. Can J Urol. 2020 Aug;27(S3):28-35. PMID: 32876000.

602. Smith WB 2nd, McCaslin IR, Gokce A, Mandava SH, Trost L, Hellstrom WJ. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013 Aug;67(8):768-80. doi: 10.1111/ijcp.12074. PMID: 23869678.

603. Viigimaa M, Vlachopoulos C, Lazaridis A, Doumas M. Management of erectile dysfunction in hypertension: tips and tricks. World J Cardiol.2014 Sep 26;6(9):908-15. doi: 10.4330/wjc.v6.i9.908. PMID: 25276292; PMCID: PMC4176800.

604. Lerner LB, McVary KT, Barry MJ et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol.2021 Oct;206(4):806-817. Doi: 10.1097/JU.0000000000002183. Epub 2021 Aug 13. Erratum in: J Urol. 2021 Nov;206(5):1339. PMID: 34384237.

605. Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J.2018 Oct;12(10):303-312. doi: 10.5489/cuaj.5616. PMID: 30332601; PMCID: PMC6192748.

Frequently asked questions